UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| Date of report (Date of earliest event reported) | March 23, 2015 |
Accelerate Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 001-31822 | 84-1072256 |
| (Commission File Number) | (IRS Employer Identification No.) |
| 3950 South Country Club, Suite 470, Tucson, Arizona | 85714 |
| (Address of principal executive offices) | (Zip Code) |
(520) 365-3100
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On March 23, 2015, Accelerate Diagnostics, Inc. (the “Company”) issued a press release announcing that it had named Juan Martin as Executive Vice President and Head of Europe, Middle East and Africa (EMEA).
Mr. Martin has significant experience leading large, global healthcare diagnostics businesses. He joins the Company from Siemens, where he served as Senior Vice President of Siemens Healthcare Diagnostics for South West Europe and General Manager of Siemens Healthcare France. In this role, he was responsible for a business with over $800 million in revenue and more than 1,500 employees. Previously, Mr. Martin held a number of successively larger roles with Siemens and Dade Behring, including General Manager of Greece and Turkey as well as Vice President of France, Belgium, Luxembourg, Greece and Turkey. Mr. Martin began his career at Coopers and Lybrand as an auditor.
A copy of the press release announcing Mr. Martin’s appointment is attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit No. | Description | |
| 99.1 | Press Release issued by the Company on March 23, 2015, entitled “Accelerate Diagnostics Names Juan Martin as Head of Europe, Middle East and Africa” (filed herewith) |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ACCELERATE DIAGNOSTICS, INC. | ||
| (Registrant) | ||
| Date: March 23, 2015 | /s/ Steve Reichling | |
| Steve Reichling | ||
| Chief Financial Officer |
EXHIBIT 99.1
Accelerate Diagnostics Names Juan Martin as Head of Europe, Middle East and Africa
TUCSON, Ariz., March 23, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc., an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms, announced today that it has named Juan Martin as Executive Vice President and Head of Europe, Middle East and Africa (EMEA).
Martin brings an exceptional track record of success in leading large, global healthcare diagnostics businesses. He joins Accelerate Diagnostics from Siemens, where he serves as Senior Vice President, Siemens Healthcare Diagnostics for South West Europe and General Manager of Siemens Healthcare France. In this role he is responsible for a business with over $800 million in revenue and more than 1500 employees. Previously, Juan held a number of successively larger roles with Siemens and Dade Behring including General Manager of Greece and Turkey as well as Vice President of France, Belgium, Luxembourg, Greece & Turkey. Martin began his career at Coopers and Lybrand as an auditor.
“We are delighted to welcome Juan to the Accelerate team,” said Lawrence Mehren, President and CEO of Accelerate Diagnostics. “With the upcoming introduction of our ID/AST system in Europe, Juan's deep experience in this key region will be invaluable as we move to establish leadership in the global clinical microbiology market.”
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX), is focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The company’s revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. For more information, visit www.acceleratediagnostics.com.
Forward-Looking Statements
This press release contains words such as “expects,” “shall,” “will,” “believes” and other similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the company’s current beliefs, known events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties that could cause the company's results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. For a full discussion of the company’s risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in Item 1A in the company’s Annual Report on Form 10-K, filed with the SEC on February 26, 2015. In addition, the company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
CONTACT:
Media Contact:
Matt Russell
Russell Public Communications
520.232.9840
mrussell@russellpublic.com
Investor Contact:
Jamien Jones
Blueprint Life Science Group
415.375.3340 Ext. 103
jjones@bplifescience.com